- Home
- VINP vs AUTL Comparison
VINP vs AUTL Comparison
Compare VINP & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VINP | AUTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 431.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VINP | AUTL |
|---|---|---|
| Price | $10.59 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $14.00 | $8.50 |
| AVG Volume (30 Days) | 77.6K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $20.11 | $85.73 |
| Revenue Next Year | $16.18 | $70.87 |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $8.66 | $1.11 |
| 52 Week High | $13.61 | $2.70 |
Technical Indicators
Market Signals| Indicator | VINP | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 46.71 |
| Support Level | $9.35 | $1.32 |
| Resistance Level | $10.87 | $1.52 |
| Average True Range (ATR) | 0.46 | 0.08 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 70.53 | 60.56 |
Price Performance
Historical ComparisonAbout VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.